ATE294774T1 - Aminoadamantan-derivate als therapeutische mittel - Google Patents

Aminoadamantan-derivate als therapeutische mittel

Info

Publication number
ATE294774T1
ATE294774T1 AT01916217T AT01916217T ATE294774T1 AT E294774 T1 ATE294774 T1 AT E294774T1 AT 01916217 T AT01916217 T AT 01916217T AT 01916217 T AT01916217 T AT 01916217T AT E294774 T1 ATE294774 T1 AT E294774T1
Authority
AT
Austria
Prior art keywords
derivatives
disorders
trauma
neurological
methods
Prior art date
Application number
AT01916217T
Other languages
English (en)
Inventor
Yuqiang Wang
Wenqing Ye
James W Larrick
Jonathan S Stamler
Stuart A Lipton
Original Assignee
Panorama Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panorama Res Inc filed Critical Panorama Res Inc
Application granted granted Critical
Publication of ATE294774T1 publication Critical patent/ATE294774T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/23—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/24—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01916217T 2000-02-22 2001-02-22 Aminoadamantan-derivate als therapeutische mittel ATE294774T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/510,099 US6444702B1 (en) 2000-02-22 2000-02-22 Aminoadamantane derivatives as therapeutic agents
PCT/US2001/005967 WO2001062706A1 (en) 2000-02-22 2001-02-22 Aminoadamantane derivatives as therapeutic agents

Publications (1)

Publication Number Publication Date
ATE294774T1 true ATE294774T1 (de) 2005-05-15

Family

ID=24029379

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01916217T ATE294774T1 (de) 2000-02-22 2001-02-22 Aminoadamantan-derivate als therapeutische mittel

Country Status (13)

Country Link
US (5) US6444702B1 (de)
EP (2) EP1568685A1 (de)
JP (1) JP4317343B2 (de)
CN (1) CN100339356C (de)
AT (1) ATE294774T1 (de)
AU (2) AU2001243271B2 (de)
BR (1) BR0108547A (de)
CA (1) CA2400916C (de)
DE (1) DE60110557T2 (de)
ES (1) ES2243468T3 (de)
MX (1) MXPA02008170A (de)
PT (1) PT1259477E (de)
WO (1) WO2001062706A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP1852113A3 (de) * 2000-12-07 2008-03-12 Neuromolecular Inc. Verfahren zur Behandlung neuropsychiatrischer Erkrankungen mit NMDA-Rezeptorantagonisten
CN1486180A (zh) * 2000-12-07 2004-03-31 纽热莫勒丘乐有限公司 用nmda受体拮抗物治疗神经精神病紊乱的方法
WO2003068726A1 (fr) * 2001-12-27 2003-08-21 Daicel Chemical Industries, Ltd. Derive amide d'amine alicyclique et procede de production de celui-ci
EP1562975A2 (de) * 2002-10-25 2005-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroide welche gruppen zur nachahmung von superoxidase dismutase sowie stickoxid donorgruppen beinhalten und ihre verwendung in der darstellung von medikamenten
WO2004041555A1 (en) 2002-11-01 2004-05-21 Bridgestone/Firestone North American Tire, Llc Method for designing tire noise pitch sequence
US20060166894A1 (en) * 2002-11-29 2006-07-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and no-donor activity
RU2231349C1 (ru) * 2003-01-15 2004-06-27 Оренбургская государственная медицинская академия Способ лечения соматической энцефалопатии
WO2005019166A2 (en) * 2003-06-11 2005-03-03 Neuromolecular, Inc. Method of targeting a therapeutic agent
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
CN100363329C (zh) * 2004-01-09 2008-01-23 南京大学 合成美金刚胺盐酸盐的方法
EP1715843A1 (de) * 2004-01-29 2006-11-02 Neuromolecular Inc. Kombination eines nmda-rezeptor-antagonisten und eines mao-hemmers oder eines gadph-hemmers zur behandlung von erkrankungen im zusammenhang mit dem zentralen nervensystem
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
JP5025468B2 (ja) 2004-06-17 2012-09-12 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン メマンチン又はネラメキサンの直接圧縮によって製造された、飲用に適した即効型錠剤
EA011446B1 (ru) * 2004-06-17 2009-02-27 Форест Лэборэтериз, Инк. Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
EP1789380A1 (de) * 2004-07-23 2007-05-30 Justus-Liebig-Universität Giessen Aminoadamantan-derivate, verfahren zu ihrer herstellung und ihre verwendung
CA2588295C (en) 2004-11-23 2013-10-22 Adamas Pharma, Llc Method and composition for administering an nmda receptor antagonist to a subject
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP2623099A1 (de) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Zusammensetzung und Verfahren zur Behandlung neurologischer Erkrankungen
ATE481096T1 (de) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
US20080009546A1 (en) * 2005-05-06 2008-01-10 Chevron U.S.A. Inc. Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders
EP1885689A1 (de) * 2005-05-06 2008-02-13 Chevron U.S.A., Inc. Diamondoidderivate mit therapeutischer wirkung
EP1898890A1 (de) * 2005-06-16 2008-03-19 Forest Laboratories, Inc. Memantin-bead-formulierung mit modifizierter und sofortiger freisetzung
EP2040676A2 (de) * 2006-07-06 2009-04-01 Forest Laboratories, Inc. Oral lösliche memantin-formulierungen
CN101450911B (zh) * 2007-11-30 2012-02-29 山东轩竹医药科技有限公司 被金刚烷取代的苯甲酸衍生物
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
KR100998525B1 (ko) 2008-03-28 2010-12-07 나노다이아몬드 주식회사 아밀로이드 올리고머 독성 억제제로서의 아다만탄 유도체
CA2994873A1 (en) 2009-12-02 2011-06-09 Adamas Pharma, Llc Amantadine compositions and methods of use
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
CN103833555B (zh) * 2012-11-23 2016-12-21 上海京新生物医药有限公司 一种盐酸美金刚的制备方法
US10555916B2 (en) 2013-01-25 2020-02-11 Case Western Reserve University NMDAR antagonist for the treatment of pervasive development disorders
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CN105294450B (zh) * 2014-05-29 2024-05-17 广州喜鹊医药有限公司 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用
JP6884800B2 (ja) * 2016-05-07 2021-06-09 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． メマンチン化合物及びその調整並びにその使用
US10214478B2 (en) * 2016-11-28 2019-02-26 Guangzhou Magpie Pharmaceuticals Co., Ltd. Amantadine nitrate compounds with neural protective effect, and preparation and medical use thereof
EP3661492B1 (de) * 2017-08-01 2024-12-25 Stuart A. Lipton Nitrosynapsin zur verwendung bei der behandlung von autistischen erkrankungen
CN111432810B (zh) 2017-11-22 2024-03-08 潘诺拉马研究公司 硝酸氨基金刚烷酯化合物和它们用于治疗cns病症的用途
CN111662216A (zh) * 2019-03-05 2020-09-15 广东东阳光药业有限公司 一种金刚烷胺类化合物的晶型及其制备方法
CN110938006A (zh) * 2019-12-04 2020-03-31 重庆植恩药业有限公司 盐酸美金刚杂质c的制备方法
WO2021231582A1 (en) * 2020-05-12 2021-11-18 Eumentis Therapeutics, Inc. Nitro-aminoadamantane compounds for the treatment of negative symptoms and cognitive impairment associated with schizophrenia
AU2022217767A1 (en) 2021-02-03 2023-08-17 The General Hospital Corporation Methods for treating autism spectrum disorder
CN117427057A (zh) * 2022-07-14 2024-01-23 广州喜鹊医药有限公司 金刚烷硝酸酯类化合物在制备预防或治疗细胞因子风暴药物中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328251A (en) 1965-12-30 1967-06-27 Du Pont Pharmaceutical compositions and methods utilizing 2-aminoadamantane and its derivatives
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
GB1175820A (en) 1966-02-18 1969-12-23 Upjohn Co Amino-Adamantane Derivatives
ES413944A1 (es) 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
US4351847A (en) 1981-06-26 1982-09-28 Pennwalt Corporation Antiviral alpha, alpha-dialkyl adamantylethylamines
US4346112A (en) 1981-06-29 1982-08-24 University Patents Inc. Composition and method for treating patients having Parkinson's Disease
JPS584718A (ja) 1981-06-30 1983-01-11 Nippon Chibagaigii Kk 新規適応症に用うる医薬製剤
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5053419A (en) 1989-03-31 1991-10-01 The Children's Medical Center Corporation Treatment of AIDS dementia, myelopathy and blindness
ES2059602T3 (es) 1989-04-14 1994-11-16 Merz & Co Gmbh & Co Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.
WO1991002810A1 (en) 1989-08-09 1991-03-07 The Children's Medical Center Corporation Nmda oxidizing agents for protecting neurons from injury
US5091391A (en) 1990-08-16 1992-02-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
US5455279A (en) 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
WO1992018112A1 (en) 1991-04-19 1992-10-29 The Children's Medical Center Corporation Method of preventing nmda receptor complex-mediated neuronal damage
US6071876A (en) 1991-04-19 2000-06-06 Children's Medical Center Corporation Method of preventing NMDA receptor complex-mediated neuronal damage
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
JPH06161125A (ja) 1992-11-17 1994-06-07 Mita Ind Co Ltd 電子写真感光体
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5677349A (en) * 1995-04-27 1997-10-14 Gilad; Gad M. Agmatine for the treatment of neurotrauma and neurodegenerative diseases
DE19528388A1 (de) * 1995-08-02 1997-02-06 Hans Peter Prof Dr Med Zenner Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
DE19531342B4 (de) 1995-08-25 2007-11-29 Merz Pharma Gmbh & Co. Kgaa Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US5776935A (en) 1996-07-25 1998-07-07 Merz & Co. Gmbh & Co. Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission
EP1574495A1 (de) * 1997-01-14 2005-09-14 Daicel Chemical Industries, Ltd. Adamantanderivate
EP0927711A4 (de) 1997-03-11 2004-12-08 Daicel Chem Adamantanderivate und verfahren zu ihrer herstellung
PT870757E (pt) 1997-04-10 2002-09-30 Pfizer Derivados de adamantano substituidos por fluoro
KR100630506B1 (ko) 1997-06-30 2006-09-29 메르츠 파마 게엠베하 운트 코. 카가아 Ｎｍｄａ 수용체 길항물질로서의 1-아미노-알킬시클로헥산 화합물, 이를 함유하는 제약학적 조성물 및 이것으로 치료하는 방법
US6071966A (en) 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
US6046232A (en) 1997-10-17 2000-04-04 Centaur Pharmaceuticals, Inc. α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
GB9726388D0 (en) 1997-12-12 1998-02-11 Cerebrus Ltd Chemical compounds
WO1999037149A1 (en) 1998-01-27 1999-07-29 Brigham & Women's Hospital Methods of treating cytotoxic damage
JP4626896B2 (ja) * 1998-02-13 2011-02-09 ダイセル化学工業株式会社 アシル化剤とそれを用いたアシル化法、及びアダマンタン誘導体
JP4215858B2 (ja) 1998-04-21 2009-01-28 ダイセル化学工業株式会社 アダマンタノール誘導体及びその製造法
EP0990632A4 (de) * 1998-04-21 2004-04-14 Daicel Chem Adamantanmethanol-derivate und verfahren zu ihrer herstellung
US6482854B1 (en) 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment
US20040009613A1 (en) 2001-02-16 2004-01-15 Ming-Ming Zhou Methods of identifying modulators of bromodomains
US7589167B2 (en) 2000-02-22 2009-09-15 J. David Gladstone Institutes ZA loops of bromodomains
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US6602862B1 (en) 2000-09-19 2003-08-05 Merz Pharma Gmbh & Co., Kgaa 1-Amino-alkylcyclohexanes as trypanocidal agents
US20040122090A1 (en) 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
CN1486180A (zh) 2000-12-07 2004-03-31 纽热莫勒丘乐有限公司 用nmda受体拮抗物治疗神经精神病紊乱的方法
US6717012B2 (en) 2001-04-02 2004-04-06 Neuromolecular, Inc. Antioxidant nitroxides and nitrones as therapeutic agents
JP2003137842A (ja) 2001-10-29 2003-05-14 Tosoh Corp α−フルオロアルキル−２−アダマンチルアクリレート類及びその製造方法
JP2003137841A (ja) 2001-10-29 2003-05-14 Tosoh Corp α−フルオロアルキル−１−アダマンチルアクリレート類及びその製造方法

Also Published As

Publication number Publication date
AU2001243271B2 (en) 2004-12-09
US20080183003A1 (en) 2008-07-31
CA2400916A1 (en) 2001-08-30
CN100339356C (zh) 2007-09-26
JP4317343B2 (ja) 2009-08-19
US6620845B2 (en) 2003-09-16
AU4327101A (en) 2001-09-03
DE60110557T2 (de) 2006-04-27
CA2400916C (en) 2012-07-10
EP1259477A1 (de) 2002-11-27
US20060106222A1 (en) 2006-05-18
US20040029929A1 (en) 2004-02-12
EP1259477B1 (de) 2005-05-04
PT1259477E (pt) 2005-08-31
US20030008889A1 (en) 2003-01-09
EP1568685A1 (de) 2005-08-31
HK1052921A1 (en) 2003-10-03
BR0108547A (pt) 2003-06-10
ES2243468T3 (es) 2005-12-01
US6444702B1 (en) 2002-09-03
US7326730B2 (en) 2008-02-05
CN1446193A (zh) 2003-10-01
WO2001062706A1 (en) 2001-08-30
DE60110557D1 (de) 2005-06-09
JP2003523989A (ja) 2003-08-12
MXPA02008170A (es) 2005-07-01

Similar Documents

Publication Publication Date Title
ATE294774T1 (de) Aminoadamantan-derivate als therapeutische mittel
BR9609019A (pt) Compostos ativos em um novo local sobre canais de cálcio operados por receptor úteis no tratamento de desordens e doenças neurológicas
HUP9904525A2 (hu) S-(-)-N-Propargil-1-amino-indán tartalmú neurológiai rendellenességek kezelésére alkalmas gyógyszerkészítmények
DE60142236D1 (de) Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung
GB9901809D0 (en) Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
ATE284208T1 (de) R-enantiomer des n-propargyl-1-aminoindan zur behandlung verschiedener krankheiten und mesylat, esylat und sulfat davon
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
HUP9802862A2 (hu) (1S,2S)-1-(4-hydroxi-fenil)-2-(4-hidroxi-4-fenil-1-piperidinil)-1-propanol-metánszulfonát-trihidrát, és ezt a vegyületet tartalmazó a központi idegrendszeri rendellenességek kezelésére alkalmas gyógyászati készítmények
PT1052246E (pt) Derivados de amino-acidos contendo fluor
ZA972496B (en) Substituted 2,3-benzodiazepin-4-ones and the use thereof.
NO961435D0 (no) Terapeutiske midler
TW200745135A (en) Therapeutic agents
MXPA02010231A (es) Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
ATE504310T1 (de) Neuroprotektive, antithrombotische und anti- entzündliche anwendungen von aktiviertem protein c
TW200635589A (en) Therapeutic agents
PL319868A1 (en) Novel method of treating diseases
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
WO2007106862A3 (en) The use of statins to stimulate neurogenesis
RU2003102437A (ru) 7-гидроксиэпиандростерон, обладающий нейропротективной активностью
WO2023107630A3 (en) Amino alcohol compounds and uses thereof
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's
MXPA01009384A (es) Composiciones farmaceuticas que comprenden un derivado de pirimidina y ciclodextrina.
DE60004835D1 (de) 7-oxo-2-azabicyclo[2.2.1]heptane als selektive muskarin-rezeptor antagonisten
DE60209192D1 (de) Inhibitore der Verzweigte-Aminosäure-abhängigen Aminotransferase und deren Verwendung in der Behandlung von Neurodegenerativen Erkrankungen
ATE361072T1 (de) N-acetyl-l-pipecolic säure als promoter der produktion des neurotrophischen faktors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1259477

Country of ref document: EP

REN Ceased due to non-payment of the annual fee